Advances in the Diagnosis and Management of Lower Genital Tract Diseases

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 1276

Special Issue Editors


E-Mail Website
Guest Editor
Preventive Gynecology Unit, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
Interests: gynecologic oncology; lower genital tract disease; HPV; colposcopy; vulvoscopy

E-Mail Website
Guest Editor
Preventive Gynecology Unit, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
Interests: gynecologic oncology; lower genital tract disease; HPV; colposcopy; ultrasound
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
UCO Gynecological and Obstetric, Department of Medicine, Surgery and Health Sciences Institute for Maternal and Child Health, IRCCS 'Burlo Garofolo', University of Trieste, Trieste, Italy
Interests: genital infections; microbiome; probiotics

Special Issue Information

Dear Colleagues,

Lower genital tract diseases represent the most frequent pathologies in the gynecological field and range from infections to benign and neoplastic lesions. The last few years have seen a growing interest in vulvovaginal diseases (recurrent infections, vulvodynia, genitourinary syndrome, lichen sclerosus, etc.) and their impact on quality of life. However, the diagnosis and treatment of several lower genital tract diseases remain a challenge. Pharmacological and non-pharmacological approaches are used, although they are not completely effective.

In the current Special Issue, we focus on new studies in the field of the diagnosis and management of vulvovaginal diseases and other rare conditions. These may include genetic and molecular biomarkers, tools for the implementation of differential diagnosis, and new strategies for the treatment of lower genital tract diseases.

Dr. Eleonora Preti
Dr. Anna Daniela Iacobone
Prof. Dr. Francesco De Seta
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vulvovaginal disease
  • vulvoscopy
  • HPV
  • quality of life
  • recurrent infections
  • diagnosis

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 3344 KiB  
Article
Expression of Preferentially Expressed Antigen in Melanoma, a Cancer/Testis Antigen, in Carcinoma In Situ of the Urinary Tract
by Shota Fujii, Mitsuaki Ishida, Kazumasa Komura, Kazuki Nishimura, Takuya Tsujino, Tomohito Saito, Yohei Taniguchi, Tomohiro Murakawa, Haruhito Azuma and Yoshinobu Hirose
Diagnostics 2023, 13(24), 3636; https://doi.org/10.3390/diagnostics13243636 - 10 Dec 2023
Viewed by 946
Abstract
Carcinoma in situ (CIS) of the urinary tract comprises 1–3% of all urothelial malignancies and is often a precursor to muscle-invasive urothelial carcinoma (UC). This study aimed to examine the expression profiles of preferentially expressed antigen in melanoma (PRAME), a cancer/testis antigen, and [...] Read more.
Carcinoma in situ (CIS) of the urinary tract comprises 1–3% of all urothelial malignancies and is often a precursor to muscle-invasive urothelial carcinoma (UC). This study aimed to examine the expression profiles of preferentially expressed antigen in melanoma (PRAME), a cancer/testis antigen, and assess its diagnostic and therapeutic applications in CIS, given that its expression in UC has been minimally studied and has not yet been analyzed in CIS. We selected consecutive patients with CIS who underwent biopsy and/or transurethral tumor resection at the Osaka Medical and Pharmaceutical University Hospital. Immunohistochemical staining for PRAME and p53 was performed. Overall, 53 patients with CIS (6 females and 47 males) were included. Notably, PRAME expression was observed in 23 of the 53 patients (43.4%), whereas it was absent in the non-neoplastic urothelial epithelium. Furthermore, no correlation was found between PRAME expression and aberrant p53 expression. Therefore, PRAME expression may serve as a useful marker for CIS of the urinary tract. Furthermore, PRAME may be a candidate for the novel therapeutic target for standard treatment-refractory CIS patients. Full article
Show Figures

Figure 1

Back to TopTop